Full-Text Search:
Home|Journal Papers|About CNKI|User Service|FAQ|Contact Us|中文
《Chinese Journal of Lung Cancer》 2011-05
Add to Favorite Get Latest Update

Efficacy and Safety of rh-Endostatin Combined with Chemotherapy versus Chemotherapy Alone for Advanced NSCLC:A Meta-analysis Review

Dedong CAO,Wei GE,Huimin WANG,Ling ZHANG,Yongfa ZHENG,Jinzhong ZHANG Department of Medical Oncology,Remmin Hospital of Wuhan University,Wuhan 430060,China  
Background and objective In recent years,there has been a large number of studies and reports about the efficacy and safety of recombinant human endostatin(rh-endostatin) ,an anti-angiogenic drug,in treatment of advanced lung cancer. Authentic assessment of rh-endostatin treatment in lung cancer is important. The aim of this study is to assess the clinical efficacy and safety of rh-endostatin combined with chemotherapy in the treatment of patients with non-small cell lung cancer(NSCLC) . Methods Cochrane systematic review methods were used in the data selection,and data were selected from the Cochrane Library,EMBASE,Medline,SCI,CBM,CNKI,and etc electronic database to get all clinical controlled trials. The retrieval time was March 2010. The objects of these randomized controlled trials were advanced NSCLC patients and in the experimental group was rh-endostatin combination chemotherapy,in the control group was chemotherapy alone to compare the efficacy of two groups. The quality of included trials were evaluated by two reviewers independently. The software RevMan 5.0 was used for meta-analyses. Results Fifteen trials with 1,326 patients were included according to the including criterion. All trials were randomized controlled trials,and two trials were adequate in reporting randomization. Thirteen trials didn’t mention the blinding methods. Meta analysis indicated that the NPE arm(Vinorelbine+cisplatin+rh-endostatin) had a different response rate compared with NP(Vinorelbine+cisplatin) arm(OR=2.16,95%CI: 1.57-2.99) . The incidences of severe leukopenia(OR=0.94,95%CI: 0.66-1.32) and severe thrombocytopenia(OR=1.00,95%CI: 0.64-1.57) and nausea and vomiting(OR=0.85,95%CI: 0.61-1.20) were similar in the NPE arm compared with those in the NP arm. The NPE plus radiotherapy(RT) arm had a similar response rate compared with NP plus RT arm(OR=2.39,95%CI: 0.99-5.79) . The incidences of leukopenia(OR=0.83,95%CI: 0.35-1.94) and thrombocytopenia(OR=0.78,95%CI: 0.19-3.16) and radiation esophagitis(OR=1.00,95%CI: 0.40-2.49) were similar in the NPE plus RT arm compared with those in the NP plus RT arm. Conclusion In the treatment of advanced NSCLC,rh-endostatin in combination with platinum-based chemotherapy improve the response rate without obviously raised side effects,however,when radiotherapy are added to NPE arm or NP arm,the response rates have a similar outcome. Owing to the small sample size and poor quality of included trials,more well-designed double-blinded randomized controlled trials should be performed.
【Fund】: 国家自然科学基金项目(No.30970860/H1615)资助~~
【CateGory Index】: R734.2
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
【Citations】
Chinese Journal Full-text Database 10 Hits
1 WANG Jinwan, SUN Yan, LIU Yongyu, YU Qitao, ZHANG Yiping, LI Kai, ZHU Yunzhong, ZHOU Qinghua, HOU Mei, GUAN Zhongzhen, LI Weilian, ZHUANG Wu, WANG Donglin, LIANG Houjie, QIN Fengzhan, LU Huishan, LIU Xiaoqing, SUN Hong, ZHANG Yanjun, WANG Jiejun, LUO Suxia, YANG Ruihe, TU Yuanrong, WANG Xiuwen, SONG Shuping, ZHOU Jingmin, YOU Lifen, WANG Jing, YAO Chen.  Cancer Hospital, Chinese Academy of Medical Sciences, Beijing 100021, P.R.China;Results of randomized, multicenter, double-blind phase Ⅲ trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients[J];Chinese Journal of Lung Cancer;2005-04
2 Haiyu MU,Chunyan SHEN,Yiling FENG Cancer center,The affiliated hospitalof Armed Police for Medical College,Tianjin 300162,China;Clinical Observation on the Target Therapy of Rh-Endostin,Combined with Chemotherapy in Advanced Non-Small Cell Lung Cancer[J];Chinese Journal of Lung Cancer;2009-07
3 CHEN Shao-jun1,HUANG Hai-xin1,LI Gui-sheng1,LI Gui-ping2(1.Department of Medical Oncology,the Fourth Affiliated Hospital of Guangxi Medical University,Liuzhou 545005,China;2.Department of Third Medical,the People's Hospital of Huizhou City,Guangdong Province,Huizhou 516002,China);CLINICAL STUDY ON ENDOSTAR COMBINED WITH VINORELBINE AND OXALIPLATIN IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER[J];Journal of Hebei Medical University;2008-06
4 HUANG Guosheng.Department of Thoracic Surgery,Affiliated Hospital of Nanyang Medical School,Nanyang 473058,Henan;The efficacy of NP plus ENDOSTAR and chemotherapy in the treatment of non-small sell lung cancer[J];Henan Journal of Surgery;2007-06
5 WANG Kai-zhong,LI Chang-yuan,LI Yang,et al(Department of Tharocic Surgery,the First Hospital of Jilin University,Changchun 130021,China);Clinical study of endu injection with NP chemotherapy in the treatment of advanced NSCLC[J];Jilin Medical Journal;2008-13
6 ;化疗联合恩度治疗非小细胞肺癌临床观察[J];Journal of Clinical Pulmonary Medicine;2009-02
7 LI Wei,YIN Yong-mei,GUO Ren-hua,LIU Ping,HUANG Pu-wen,LU Kai-hua,LIU Ling-xiang,SHU Yong-qian.Department of Oncology,the First Affiliated Hospital of Nanjing Medicial University,Nanjing 210029,China;Endostar combined with TP or GP regimen in advanced non-small cell lung cancer patients[J];Chinese Clinical Oncology;2008-09
8 TANG Zhi,YU Zhong-hua,YANG Zhi-xiong,WANG Zhen-nan,ZHOU He-chao,LI Shu-hui.Cancer Center,the Affiliated Hospital of Guangdong Medical College,Zhanjiang 524001,China;Observation of rh-endostatin combined with TC regimen for non-small cell lung cancer[J];Chinese Clinical Oncology;2009-04
9 ZHANG Te,LIU Da-hai,WANG Bin,et al.The Central Hospital,Huzhou 313000,China;Latest Efficacy and Safety of YH-16 Combined with GP for Advanced Non-small Cell Lung Cancer[J];Chinese General Practice;2009-11
10 ;恩度联合化疗治疗中晚期非小细胞肺癌的疗效观察[J];Chinese Journal of Practical Internal Medicine;2007-19
【Co-citations】
Chinese Journal Full-text Database 10 Hits
1 Anhui Provincial Construction Hospital,Hefei 230022,AnhuiXU Li-ping;Nursing and Observation of 10 Cases of Advanced Stage Tumor Patients Treated with Endostar[J];Journal of Anhui Health Vocational & Technical College;2008-06
2 Li Yong Zhang Xiangru Sun Yan Cancer Institute & Hospital,CAMS & PUMC,Beijing 100021,China;Advances of targeted therapy in the treatment of non-small cell lung cancer[J];Oncology Progress;2007-02
3 Yuan Xia~1 Zhang Dongsheng~1 Yuan Zhongyu~1 He Ying~2 Ma Huimin~2 Li Jun~2 Jiang Wenqi~(1#) 1 State Key Laboratory of Oncology in South China,Department of Medical Oncology,Cancer Center,Sun Yat-sen University,Guangzhou,Guangdong,510060,P.R.China 2 Huizhou Municipal Center Hospital,Huizhou,Guangdnng,516001,P.R.China;Endostar combined with chemotherapy in the treatment of HER-2 negative breast cancer[J];Oncology Progress;2007-06
4 Li Yong Sun Yan Zhang Xiangru Cancer Institute & Hospital,CAMS&PUMC,Beijing 100021,China;The andvances of tumor anti-angiogenetic therapy[J];Oncology Progress;2008-01
5 Li Lixia~# Zheng Jihua Zhang Weimin Department of Oncology,Guangzhou General Hospital of PLA,Guangzhou 510010,China;Clinical application of recombinant human endostatin[J];Oncology Progress;2009-02
6 JIANG Kui,SUN Xiu-hua,YANG Xiao-yan,ZHANG Xian,ZHANG Yang(Department of Oncology,the Second Affiliated Hospital of Dalian Medical University,Dalian 116027,China);Vinorelbine and cisplatin regimein in treating elder patients with advanced non-small cell lung cancer[J];Journal of Dalian Medical University;2008-01
7 QIN Jing1, ZHANG Peng-hai1, QIAN Xin-yu1, KANG Shi-jun1, LUO Rong-cheng1, Wang Yue-gang2 1Department of Oncology, 2Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China;Assessment of the cardiotoxicity of recombinant human endostatin using myocardial biochemical markers in cancer patients[J];Journal of Southern Medical University;2008-06
8 WANG Jinwan, SUN Yan, LIU Yongyu, YU Qitao, ZHANG Yiping, LI Kai, ZHU Yunzhong, ZHOU Qinghua, HOU Mei, GUAN Zhongzhen, LI Weilian, ZHUANG Wu, WANG Donglin, LIANG Houjie, QIN Fengzhan, LU Huishan, LIU Xiaoqing, SUN Hong, ZHANG Yanjun, WANG Jiejun, LUO Suxia, YANG Ruihe, TU Yuanrong, WANG Xiuwen, SONG Shuping, ZHOU Jingmin, YOU Lifen, WANG Jing, YAO Chen.  Cancer Hospital, Chinese Academy of Medical Sciences, Beijing 100021, P.R.China;Results of randomized, multicenter, double-blind phase Ⅲ trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients[J];Chinese Journal of Lung Cancer;2005-04
9 SUN Yan, LIN Hongsheng, ZHU Yunzhong, FENG Jifeng, CHEN Zhengtang, LI Gongshu, ZHANG Xiangru, ZHANG Zongqi, TANG Junfang, SHI Meiqi, HAO Xuezhi, HAN Hui. *Department of Medical Oncology, Cancer Hospital/Institute, Chinese Academy of Medical Sciences & PUMC, Beijing 100021, P.R.China;A randomized, prospective, multi-centre clinical trial of NP regimen (vinorelbine+cisplatin) plus Gensing Rg3 in the treatment of advanced non-small cell lung cancer patients[J];Chinese Journal of Lung Cancer;2006-03
10 Qinghua ZHOU Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin 300052, China;New Year Wishes[J];Chinese Journal of Lung Cancer;2009-01
China Proceedings of conference Full-text Database 3 Hits
1 ;Five reports on treatingⅢstage of NSCLC with En-du and Kang-lai-te inject[A];[C];2007
2 PAN Yan (Department of Pharmacy,Shanghai Chest Hospital,200030);Development in clinical research of Endostar for malignant tumor[A];[C];2009
3 PAN Yan (Department of Pharmacy,Shanghai Chest Hospital,200030);Development in clinical research of Endostar for malignant tumor[A];[C];2010
【Secondary Citations】
Chinese Journal Full-text Database 10 Hits
1 Teng Xiao Yu, Zhou Ning Ning, Su Yi Shun, Zhou Zhong Mei, Liu Dong Geng, He You Jian Department of Medical Oncology, Cancer Center,Sun Yat sen University,Guangzhou,Guangdong, 510060,P.R.China;Comparison of Cisplatin Combined with Gemcitabine Versus Cisplatin Combined with Vinorelbine Regimen for Treatment of Patients with Advanced Non-Small Cell Lung Cancer[J];Chinese Journal of Cancer;2003-04
2 LIU Lian,WANG Xiu-Wen,LI Li, ZHANG Xin, ZHANG Wen-Dong, YU Xue-Jun Department of Chemotherapy, Cancer Center, Qilu Hospital of Shandong University, Jinan,Shandong, 250012, P. R. China;A Randomized Comparative Trial of Three Combined Regimens Containing Cisplatin for Treatment of Advanced Non-Small Cell Lung Cancer[J];Chinese Journal of Cancer;2006-08
3 SHI Heling, XU Liyan, LIU Zhe. Department of Medical Oncology, Beijing Tuberculosis and Thoracic Tumor Hospital, Beijing 101149, P.R.China;Phase Ⅱ clinical trial of homemade human rh-endostatin in the treatment of patients with stage ⅢB--Ⅳ non-small cell lung cancer[J];Chinese Journal of Lung Cancer;2004-04
4 WANG Jinwan, SUN Yan, LIU Yongyu, YU Qitao, ZHANG Yiping, LI Kai, ZHU Yunzhong, ZHOU Qinghua, HOU Mei, GUAN Zhongzhen, LI Weilian, ZHUANG Wu, WANG Donglin, LIANG Houjie, QIN Fengzhan, LU Huishan, LIU Xiaoqing, SUN Hong, ZHANG Yanjun, WANG Jiejun, LUO Suxia, YANG Ruihe, TU Yuanrong, WANG Xiuwen, SONG Shuping, ZHOU Jingmin, YOU Lifen, WANG Jing, YAO Chen.  Cancer Hospital, Chinese Academy of Medical Sciences, Beijing 100021, P.R.China;Results of randomized, multicenter, double-blind phase Ⅲ trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients[J];Chinese Journal of Lung Cancer;2005-04
5 REN Li, ZHU Jiang, GOU Hongfeng, YAN Xi, HE Jianping. Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R.China;A randomized clinical trial of chemotherapy combined with oxaliplatin and cisplatin plus navelbine in the treatment of advanced non-small cell lung cancer[J];Chinese Journal of Lung Cancer;2005-06
6 Department of Medical Oncalogy:Beijing Hospital,Beijing 100730,China CHENG Gang;Progress of clinical research in"tailor"chemotherapy for non-small-cell lung cancer[J];Chinese Journal of Lung Cancer;2008-01
7 AI Xinghao LU Shun Shanghai Chest Hospital Affiliated to Shanghai Jiaotong University,Shanghai 200030,China;Advances of maintenance chemotherapy on advanced non-small cell lung cancer[J];Chinese Journal of Lung Cancer;2008-01
8 Song Ziyan,Bian Baoxiang,Yang Chengxi(Department of Medical Oncology,the First People's Hospital of Lianyungang,Lianyungang 222002,China);Observation of Short-Term Effects of YH-16 Combined with GP Regimen for Non-Small Cell Lung Cancer[J];Journal of Basic and Clinical Oncology;2007-06
9 LIU Xiu-feng,QIN Shu-kui,WANG Lin,QIAN Jun,CHEN Ying-xia,HE Ze-ming,GONG Xin-lei,YANG Liu-qing.Department of Medical Oncology,PLA Cancer Center,81 Hospital of PLA,Nanjing 210002,China;Endostar combined with chemotherapy on the multiple kinds of advanced malignancies[J];Chinese Clinical Oncology;2007-04
10 QIN Shu-kui,LIU Xiu-feng,WANG Lin,CHEN Ying-xia,QIAN Jun,HUA Hai-qing,GONG Xin-lei,YANG Liu-qing,HE Ze-ming.Department of Medical Oncology,PLA Cancer Center,81 Hospital of PLA,Nanjing 210002,China;Clinical study of endostar combined with chemotherapy for the multiple kind of advanced malignancies except lung cancer[J];Chinese Clinical Oncology;2007-10
©2006 Tsinghua Tongfang Knowledge Network Technology Co., Ltd.(Beijing)(TTKN) All rights reserved